Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Receives UKMHRA Approval for Mouth-dissolving Strips to Treat Illnesses
Details : Betahistine dihydrochloride is an antivertigo agent, which is act as the histamine receptor inhibitor, which is indicated for the reduction of recurrent vertigo episodes associated with Meniere's disease in patients 18 years old and above.
Product Name : Betahistine Dihydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2023
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2021
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2020
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2020
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
Details :
Product Name : AM-125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable